These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22431809)

  • 21. Efficacy of tigecycline pleurodesis: a comparative experimental study.
    Daddi N; Vannucci J; Maggio C; Giontella A; Bravi I; Marziani F; Capozzi R; Ragusa M; Bufalari A; Puma F
    J Surg Res; 2011 Aug; 169(2):e109-18. PubMed ID: 20934718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extreme alkaline phosphatase elevation associated with tigecycline.
    Bonilla MF; Avery RK; Rehm SJ; Neuner EA; Isada CM; van Duin D
    J Antimicrob Chemother; 2011 Apr; 66(4):952-3. PubMed ID: 21393193
    [No Abstract]   [Full Text] [Related]  

  • 23. New antibiotic approved for MRSA.
    Senior K
    Lancet Infect Dis; 2005 Aug; 5(8):474. PubMed ID: 16094734
    [No Abstract]   [Full Text] [Related]  

  • 24. [Tigecycline--a new antibiotic].
    Skibeli V; Aaløkken I; Lingaas E; Midtvedt T; Solberg CO; Melby KK
    Tidsskr Nor Laegeforen; 2010 Aug; 130(16):1624-6. PubMed ID: 20805861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tigecycline-induced acute pancreatitis: case report and literature review.
    Hung WY; Kogelman L; Volpe G; Iafrati M; Davidson L
    Int J Antimicrob Agents; 2009 Nov; 34(5):486-9. PubMed ID: 19540093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline.
    Nicolau DP
    Expert Opin Pharmacother; 2009 May; 10(7):1213-22. PubMed ID: 19405794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with adherence to guidelines for the use of tigecycline in a tertiary care hospital.
    Grau S; Conde-Estévez D; Luque S; Alvarez-Lerma F; Horcajada JP; Mateu-De Antonio J; Berenguer N; Salas E
    J Chemother; 2010 Oct; 22(5):339-44. PubMed ID: 21123158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of tigecycline trials announced.
    McConnell J
    Lancet Infect Dis; 2004 Dec; 4(12):717. PubMed ID: 15593443
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.
    Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G
    Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric acute pancreatitis related to tigecycline.
    Prot-Labarthe S; Youdaren R; Benkerrou M; Basmaci R; Lorrot M
    Pediatr Infect Dis J; 2010 Sep; 29(9):890-1. PubMed ID: 20720475
    [No Abstract]   [Full Text] [Related]  

  • 31. Tigecycline (Tygacil).
    Obstet Gynecol; 2006 Jan; 107(1):178-80. PubMed ID: 16394058
    [No Abstract]   [Full Text] [Related]  

  • 32. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline.
    Pieringer H; Schmekal B; Biesenbach G; Pohanka E
    Ann Hematol; 2010 Oct; 89(10):1063-4. PubMed ID: 20174923
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
    Chuang YC; Chang CM; Aradhya S; Nagari B; Pai V; Dartois N; Jouve S; Cooper A
    J Microbiol Immunol Infect; 2011 Apr; 44(2):116-24. PubMed ID: 21439514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tigecycline: a critical analysis.
    Stein GE; Craig WA
    Clin Infect Dis; 2006 Aug; 43(4):518-24. PubMed ID: 16838243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute pancreatitis related to tigecycline: case report and review of the literature.
    Gilson M; Moachon L; Jeanne L; Dumaine V; Eyrolle L; Morand P; Ben m'Rad M; Salmon D
    Scand J Infect Dis; 2008; 40(8):681-3. PubMed ID: 18979610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Curcio D; Verde PE
    J Antimicrob Chemother; 2011 Dec; 66(12):2893-5; author reply 2895-6. PubMed ID: 21921075
    [No Abstract]   [Full Text] [Related]  

  • 38. Comment on: Efficacy and safety of tigecycline: a systematic review and meta-analysis.
    Scaglione F
    J Antimicrob Chemother; 2011 Dec; 66(12):2892-3; author reply 2895-6. PubMed ID: 21862475
    [No Abstract]   [Full Text] [Related]  

  • 39. Tigecycline: what is it, and where should it be used?
    Livermore DM
    J Antimicrob Chemother; 2005 Oct; 56(4):611-4. PubMed ID: 16120626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Experience with tigecycline in the treatment of multiresistant germs in the ICU].
    Curiel Balsera E; Poullet Brea AM; Prieto Palomino MÁ
    Med Intensiva; 2011; 35(5):319-20. PubMed ID: 21130538
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.